


BIM 23042 TFA

Cat. No.:	HY-103277A
Molecular Formula:	$C_{63}H_{73}N_{11}O_9S_2 \cdot xC_2HF_3O_2$
Sequence:	{DNaI}-Cys-Tyr-{DTrp}-Lys-Val-Cys-{NaI}-NH ₂ (Disulfide bridge:Cys2-Cys7)
Sequence Shortening:	{DNaI}-CY-{DTrp}-KVC-{NaI}-NH ₂ (Disulfide bridge:Cys2-Cys7)
Target:	Bombesin Receptor
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 6 mg/mL (Need ultrasonic)
-----------------	--

BIOLOGICAL ACTIVITY

Description	BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release ^{[1][2][3]} .
--------------------	---

REFERENCES

- [1]. R R Ryan, et al. Pharmacological profiles of two bombesin analogues in cells transfected with human neuromedin B receptors. *Eur J Pharmacol.* 1996 Jun 13;306(1-3):307-14.
- [2]. Santosh K Mishra, et al. A nociceptive signaling role for neuromedin B. *J Neurosci.* 2012 Jun 20;32(25):8686-95.
- [3]. M Orbuch, et al. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. *Mol Pharmacol.* 1993 Oct;44(4):841-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA